News | July 06, 2023
Croda completes acquisition of Solus Biotech
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The company is already marketing the 4 mg and 10 mg strengths
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The company will submit its comprehensive response on these observations to the USFDA
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
The inspection closed with zero observations
Subscribe To Our Newsletter & Stay Updated
